139 related articles for article (PubMed ID: 19438482)
21. Decreased expression of CCAAT/enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases.
Qian J; Chen Z; Lin J; Wang W; Cen J
Leuk Res; 2005 Dec; 29(12):1435-41. PubMed ID: 16005964
[TBL] [Abstract][Full Text] [Related]
22. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression.
Sridhar K; Ross DT; Tibshirani R; Butte AJ; Greenberg PL
Blood; 2009 Nov; 114(23):4847-58. PubMed ID: 19801443
[TBL] [Abstract][Full Text] [Related]
23. Aberrant alternative splicing of interferon regulatory factor-1 (IRF-1) in myelodysplastic hematopoietic progenitor cells.
Maratheftis CI; Bolaraki PE; Giannouli S; Kapsogeorgou EK; Moutsopoulos HM; Voulgarelis M
Leuk Res; 2006 Sep; 30(9):1177-86. PubMed ID: 16483648
[TBL] [Abstract][Full Text] [Related]
24. Molecular pathways mediating MDS/AML with focus on AML1/RUNX1 point mutations.
Harada Y; Harada H
J Cell Physiol; 2009 Jul; 220(1):16-20. PubMed ID: 19334039
[TBL] [Abstract][Full Text] [Related]
25. Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells.
Qi X; Chen Z; Liu D; Cen J; Gu M
Int J Mol Med; 2008 Jul; 22(1):61-8. PubMed ID: 18575777
[TBL] [Abstract][Full Text] [Related]
26. LEF1-AS1, long non-coding RNA, inhibits proliferation in myeloid malignancy.
Congrains-Castillo A; Niemann FS; Santos Duarte AS; Olalla-Saad ST
J Cell Mol Med; 2019 Apr; 23(4):3021-3025. PubMed ID: 30770626
[TBL] [Abstract][Full Text] [Related]
27. Expression and inducibility of cytoprotective heat shock proteins in the bone marrow of patients with myelodysplastic syndrome: correlation with disease progression.
Michalopoulou S; Micheva I; Karakantza M; Kouraklis-Symeonidis A; Mouzaki A; Zoumbos NC
Haematologica; 2006 Dec; 91(12):1714-6. PubMed ID: 17145614
[TBL] [Abstract][Full Text] [Related]
28. AML/MDS with 11q/MLL amplification show characteristic gene expression signature and interplay of DNA copy number changes.
Zatkova A; Merk S; Wendehack M; Bilban M; Muzik EM; Muradyan A; Haferlach C; Haferlach T; Wimmer K; Fonatsch C; Ullmann R
Genes Chromosomes Cancer; 2009 Jun; 48(6):510-20. PubMed ID: 19306356
[TBL] [Abstract][Full Text] [Related]
29. Overexpression of the novel oncogene SALL4 and activation of the Wnt/beta-catenin pathway in myelodysplastic syndromes.
Shuai X; Zhou D; Shen T; Wu Y; Zhang J; Wang X; Li Q
Cancer Genet Cytogenet; 2009 Oct; 194(2):119-24. PubMed ID: 19781444
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation.
Hopfer O; Komor M; Koehler IS; Schulze M; Hoelzer D; Thiel E; Hofmann WK
Exp Hematol; 2007 May; 35(5):712-23. PubMed ID: 17577921
[TBL] [Abstract][Full Text] [Related]
31. Neutrophil elastase is severely down-regulated in severe congenital neutropenia independent of ELA2 or HAX1 mutations but dependent on LEF-1.
Skokowa J; Fobiwe JP; Dan L; Thakur BK; Welte K
Blood; 2009 Oct; 114(14):3044-51. PubMed ID: 19620402
[TBL] [Abstract][Full Text] [Related]
32. Abnormal expression of C3ORF9 gene in patients with myelodysplastic syndromes.
Karadonta AV; Alexandrakis MG; Kourelis TV; Manola A; Garlemou K; Stathakis NE; Kyriakou D
Int J Immunopathol Pharmacol; 2009; 22(3):787-93. PubMed ID: 19822096
[TBL] [Abstract][Full Text] [Related]
33. MEL1S, not MEL1, is overexpressed in myelodysplastic syndromes patients with t(1;3)(p36;q21).
Xiao Z; Zhang M; Liu X; Zhang Y; Yang L; Hao Y
Leuk Res; 2006 Mar; 30(3):332-4. PubMed ID: 16102824
[TBL] [Abstract][Full Text] [Related]
34. A distinct expression of various gene subsets in CD34+ cells from patients with early and advanced myelodysplastic syndrome.
Vasikova A; Belickova M; Budinska E; Cermak J
Leuk Res; 2010 Dec; 34(12):1566-72. PubMed ID: 20303173
[TBL] [Abstract][Full Text] [Related]
35. Genetic interaction between Lef1 and Alx4 is required for early embryonic development.
Boras-Granic K; Grosschedl R; Hamel PA
Int J Dev Biol; 2006; 50(7):601-10. PubMed ID: 16892173
[TBL] [Abstract][Full Text] [Related]
36. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome.
Sternberg A; Killick S; Littlewood T; Hatton C; Peniket A; Seidl T; Soneji S; Leach J; Bowen D; Chapman C; Standen G; Massey E; Robinson L; Vadher B; Kaczmarski R; Janmohammed R; Clipsham K; Carr A; Vyas P
Blood; 2005 Nov; 106(9):2982-91. PubMed ID: 16076868
[TBL] [Abstract][Full Text] [Related]
37. Accelerated cellular senescence in myelodysplastic syndrome.
Wang YY; Cen JN; He J; Shen HJ; Liu DD; Yao L; Qi XF; Chen ZX
Exp Hematol; 2009 Nov; 37(11):1310-7. PubMed ID: 19748549
[TBL] [Abstract][Full Text] [Related]
38. Octamer-binding transcription factor-1 gene is upregulated in primary varicose veins.
Jeong GA; Choi ET; Chang JH
Ann Vasc Surg; 2008 Jan; 22(1):115-20. PubMed ID: 18083338
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of high-Km 5'-nucleotidase (cN-II) mRNA expression in high-risk myelodysplastic syndrome.
Suzuki K; Sugawara T; Oyake T; Uchiyama T; Aoki Y; Tsukushi Y; Onodera S; Ito S; Murai K; Ishida Y
Leuk Res; 2007 Oct; 31(10):1343-9. PubMed ID: 17350683
[TBL] [Abstract][Full Text] [Related]
40. Bone marrow glycophorin-positive erythroid cells of myelodysplastic patients responding to high-dose rHuEPO therapy have a different gene expression pattern from those of nonresponders.
Cortelezzi A; Colombo G; Pellegrini C; Silvestris I; Moronetti Mazzeo L; Bosari S; Lambertenghi Deliliers G; Fracchiolla NS
Am J Hematol; 2008 Jul; 83(7):531-9. PubMed ID: 18383321
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
